´ë±Ô¸ð ÀÓ»ó½ÃÇèÀÎ TORCH ¿¬±¸¿¡¼ Áߵ ÀÌ»óÀÇ ¸¸¼ºÆó¼â¼ºÆóÁúȯ(COPD) ȯÀÚ¿¡¼ ÈíÀÔ ½ºÅ×·ÎÀ̵å(inhaled corticosteroid, ICS)¿Í Áö¼Ó¼º º£Å¸-2 ÀÛ¿ëÁ¦(long-acting beta-2 agonist, LABA)ÀÇ º¹ÇÕ¿ä¹ý(LABA/ICS)Àº ´ÜÀÏ ±â°üÁöÈ®ÀåÁ¦ÀÎ LABA »ç¿ë¿¡ ºñÇØ Áõ»ó°ú Æó±â´ÉÀ» Çâ»ó½ÃÅ°°í COPD ¾Çȸ¦ °¨¼Ò½ÃÄ×´Ù.1 ÀÌ·± ¿¬±¸°á°ú·Î ICS/LABA´Â COPD ȯÀÚÀÇ Ä¡·áÁ¦·Î ÃÖ±Ù±îÁöµµ ³Î¸® »ç¿ëµÅ ¿Ô´Ù.2
ÇÏÁö¸¸ ICS »ç¿ëÀ¸·Î ÀÎÇØ ¹ß»ýÇÒ ¼ö ÀÖ´Â ºÎÀÛ¿ëµµ °í·ÁÇØ¾ß Çϴµ¥, ÈçÈ÷ ±¸° Áø±ÕÁõ, ¼ºÁ¶º¯È µîÀÌ ÀÖ´Ù. ÃÖ±ÙÀÇ °¡Àå Å« °ü½É ´ë»óÀº ICS »ç¿ëÀ¸·Î ÀÎÇÑ Æó·Å ¹ß»ý À§ÇèÀÇ Áõ°¡´Ù.1 ƯÈ÷, °í·É, üÁú·®Áö¼ö£¼25kg/§³, 1ÃÊ°Á¦È£±â·®(FEV©û)£¼50% predictedÀÇ ³·Àº Æó±â´É, ÇöÀç Èí¿¬ÀÚ, °ú°Å ¾Çȳª Æó·ÅÀÇ º´·ÂÀÌ ÀÖ´Â °æ¿ì, ICS »ç¿ëÀ¸·Î ÀÎÇÑ Æó·ÅÀÇ À§ÇèÀÌ À¯ÀÇÇÏ°Ô Áõ°¡ÇÑ´Ù.3, 4 ¶ÇÇÑ Æó·Å ÀÌ¿Ü¿¡µµ ICSÀÇ »ç¿ëÀº °áÇÙ ¹ß»ýÀÇ À§Çèµµ¸¦ ¾à 20∼30% Áõ°¡½ÃŲ´Ù.5
ÃÖ±Ù ¼ö³â »çÀÌ¿¡ LABA¿Í Áö¼Ó¼º Ç×Äݸ°Á¦(long-acting muscarinic antagonist, LAMA)ÀÇ ÀÌÁß ±â°üÁöÈ®ÀåÁ¦(LABA/LAMA dual bronchodilator)°¡ µµÀԵưí, ´ë±Ô¸ð ¹«ÀÛÀ§ ´ëÁ¶ ÀÓ»ó½ÃÇè¿¡¼ LABA/ICS(salmeterol/fluticasone)¿¡ ºñÇØ LABA/LAMA(indacaterol/glycopyrronium)°¡ COPD ¾Çȸ¦ 17% Á¤µµ ÁÙÀÎ´Ù°í º¸°íµÆ´Ù.6 µû¶ó¼ 2017³âµµ ¼¼°èÆó¼â¼ºÆóÁúȯ±â±¸(GOLD) °¡À̵å¶óÀο¡¼´Â ÀæÀº ¾ÇÈ°¡ ÀÖ´Â Group D ȯÀÚ¿¡¼ Ãʱâ Ä¡·á·Î LABA/LAMA¸¦ ±Ç°íÇÏ¿´°í, ÀÌÈÄ¿¡µµ ¾ÇÈ°¡ Ãß°¡·Î ¹ß»ýÇÒ °æ¿ì¿¡ LABA/LAMA/ICSÀÇ 3Á¦ ¿ä¹ýÀ» ±Ç°íÇß´Ù. ´ëÇÑ°áÇÙ ¹× È£Èí±âÇÐȸ 2018³â °³Á¤ COPD Áø·á Áöħ¿¡¼µµ FEV©û£¼60% predictedÀ̰ųª ÀæÀº ¾ÇÈ°¡ ÀÖ´Â ´Ù±º ȯÀÚ¿¡¼ LABA/LAMA¸¦ 1Â÷Ä¡·á·Î ±Ç°íÇß°í ÀÌÈÄ¿¡µµ ¾ÇÈ°¡ Ãß°¡·Î ¹ß»ýÇÒ °æ¿ì¿¡ LABA/LAMA/ICSÀÇ 3Á¦ ¿ä¹ýÀ» ±Ç°íÇß´Ù.
ÀÌ·± 3Á¦¿ä¹ýÀ» ±Ç°íÇÏ´Â ±Ù°Å°¡ µÇ´Â ´ë±Ô¸ð ÀÓ»ó ¿¬±¸°á°úµéÀº 2018³â¿¡ ¹ßÇ¥µÆ´Ù. ´ÜÀÏ ÈíÀԱ⸦ ÀÌ¿ëÇÑ 3Á¦¿ä¹ýÀ» LABA/LAMAÀÎ ÀÌÁß ±â°üÁöÈ®ÀåÁ¦¿Í ºñ±³ÇÑ Àӻ󿬱¸µé Áß TRIBUTE ¿¬±¸´Â 40¼¼ ÀÌ»óÀÇ Èí¿¬·ÂÀÌ ÀÖ¾ú´ø COPD ȯÀÚ·Î Áõ»óÀÌ ÀÖ°í(CAT Á¡¼ö 10Á¡ ÀÌ»ó) FEV©û 50% predicted ¹Ì¸¸ÀÌ¸é¼ Áö³ÇØ¿¡ Áߵ ȤÀº ÁßÁõ ¾ÇÈ°¡ 1ȸ ÀÌ»ó ÀÖ°í, ¿¬±¸ ½ºÅ©¸®´×Àü¿¡ Àû¾îµµ 2´Þ µ¿¾È ICS/LABA, ICS/LAMA ¶Ç´Â LAMA/LABA¸¦ »ç¿ëÇßÀ¸³ª, 3Á¦¿ä¹ýÀ» »ç¿ëÇÏÁö ¾Ê¾Ò´ø ȯÀÚµéÀ» ´ë»óÀ¸·Î Çß´Ù.7 ¿¬±¸°á°ú, 3Á¦¿ä¹ýÀÎ beclomethasone/formoterol/glycopyrroniumÀº ÀÌÁß ±â°üÁöÈ®ÀåÁ¦ÀÎ indacaterol/glycopyrronium °ú ºñ±³ÇÏ¿´À» ¶§ Áߵ ȤÀº ÁßÁõ ¾ÇÈ ¹ß»ýÀ» 15% Á¤µµ À¯ÀÇÇÏ°Ô °¨¼Ò½ÃÄ×À¸¸ç, Æó·Å ¹ß»ý·üÀº ¾ç ±º¿¡¼ °øÈ÷ 4%·Î Â÷ÀÌ°¡ ¾ø¾ú´Ù.
´Ù¸¥ Àӻ󿬱¸ÀÎ IMPACT´Â 40¼¼ ÀÌ»óÀÎ 10°©³â ÀÌ»óÀÇ Èí¿¬·ÂÀÌ ÀÖ´Â COPD ȯÀÚ·Î, Áõ»óÀÌ ÀÖ°í(CAT Á¡¼ö 10Á¡ ÀÌ»ó), FEV©û 50% predicted ¹Ì¸¸ÀÎ °æ¿ì Áö³ÇØ¿¡ 1ȸÀÌ»óÀÇ Áߵ ȤÀº ÁßÁõ ¾ÇÈ°¡ 1ȸ ÀÌ»ó ÀÖ¾ú°Å³ª, FEV©û 50~80% predictedÀÎ °æ¿ì Áö³ÇØ¿¡ 2ȸ ÀÌ»óÀÇ Áߵ ȤÀº 1ȸ ÀÌ»óÀÇ ÁßÁõ ¾ÇÈ°¡ ÀÖ¾ú´ø ȯÀÚ¸¦ ´ë»óÀ¸·Î Çß´Ù.8 ÀÌ´Â ´ÜÀÏ ÈíÀԱ⸦ ÀÌ¿ëÇÑ 3Á¦¿ä¹ý°ú LABA/KAMAÀÎ ÀÌÁß ±â°üÁöÈ®ÀåÁ¦¸¦ °°Àº ÈíÀÔ±â·Î ºñ±³ÇÑ Ã¹ Àӻ󿬱¸´Ù. ¿¬±¸ °á°ú 3Á¦¿ä¹ýÀÎ fluticasone furoate/vilanterol/umeclidiniumÀº ÀÌÁß ±â°üÁöÈ®ÀåÁ¦ÀÎ vilanterol/umeclidinium¿¡ ºñÇØ Áߵ ȤÀº ÁßÁõ ¾ÇÈÀÇ ¹ß»ýÀ» 25% Á¤µµ À¯ÀÇÇÏ°Ô °¨¼Ò½ÃÄ×°í, ÀÔ¿øÀ» ¿äÇÒ Á¤µµÀÇ ÁßÁõ ¾ÇÈÀÇ ¹ß»ý ¶ÇÇÑ 34% Á¤µµ À¯ÀÇÇÏ°Ô °¨¼Ò½ÃÄ×´Ù. ±×·¯³ª Æó·Å ¹ß»ý·üÀº 3Á¦¿ä¹ý Ä¡·á±º¿¡¼ 8%·Î ÀÌÁß ±â°üÁöÈ®ÀåÁ¦ Ä¡·á±ºÀÇ 5%¿¡ ºñÇØ À¯ÀÇÇÏ°Ô ³ô¾Ò´Ù.
µû¶ó¼ 3Á¦¿ä¹ýÀÇ ÀÓ»óÀûÀÎ À̵æ°ú ICS·Î ÀÎÇÑ ºÎÀÛ¿ë À§Çè(ƯÈ÷ Æó·Å)À» °í·ÁÇßÀ» ¶§ ICS »ç¿ëÀÇ È¿°ú°¡ Ŭ °ÍÀ¸·Î ¿¹»óµÇ´Â ȯÀÚµéÀ» ¼±ÅÃÇÏ´Â °ÍÀÌ Áß¿äÇÏ°Ô µÇ¾ú´Ù. °øÅëÀûÀ¸·Î 1)õ½Ä º´·Â 2) ÀæÀº ¾ÇÈ º´·Â(¿¬ 2ȸ ÀÌ»ó) 3) ¸»ÃÊ Ç÷¾× È£»ê±¸ Áõ°¡(300cells/μL ÀÌ»ó) µîÀÌ ICS »ç¿ëÀÇ ÁÁÀº ¹ÝÀÀÀ» ¿¹ÃøÇÒ ¼ö ÀÖ´Â ÀÎÀÚ·Î ¾Ë·ÁÁ® ÀÖ°í, ƯÈ÷ ÀæÀº ¾ÇÈ º´·Â°ú ¸»ÃÊ Ç÷¾× È£»ê±¸ Áõ°¡°¡ ÇÔ²² ÀÖÀ» °æ¿ì¿¡´Â 3Á¦¿ä¹ýÀÇ À̵æÀÌ ´õ¿í ¶Ñ·ÇÇÑ °ÍÀ¸·Î º¸°í ÀÖ´Ù.9 µû¶ó¼ ÀÌ·¯ÇÑ ÀÎÀÚ°¡ ¾ø´Â ȯÀÚ¶ó¸é, Æó±â´É °¨¼Ò³ª 1ȸÀÇ ¾ÇÈ º´·Â¸¸À» ¹ÙÅÁÀ¸·Î Á¶±â¿¡ 3Á¦¿ä¹ýÀ» »ç¿ëÇÏ´Â °Í º¸´Ù´Â ¸ÕÀú LABA/LAMA »ç¿ëÀ» ±ÇÇÏ°í, µ¿½Ã¿¡ ´ÙÀ½ÀÇ »çÇ×À» °í·ÁÇØ º¸¾Æ¾ß ÇÑ´Ù. ±Ý¿¬ ¿©ºÎ¿Í ÈíÀԱ⸦ Á¤È®ÇÏ°Ô ¸ÅÀÏ »ç¿ëÇÏ°í ÀÖ´ÂÁö È®ÀÎÇغ¸´Â °ÍÀÌ °¡Àå Áß¿äÇϸç, µ¿¹ÝµÈ Áúȯ (comorbid disease)À» °¨º°ÇØ¾ß Çϴµ¥ ƯÈ÷ ½ÉÇ÷°ü°è Áúȯ°ú Æó¾ÏÀ» °¨º°ÇØ¾ß ÇÑ´Ù. ¸¶Áö¸·À¸·Î, 3Á¦ ¿ä¹ý¿¡µµ ºÒ±¸ÇÏ°í ¾ÇÈ°¡ Áö¼ÓµÇ°í Æó·ÅÀÌ ¹ß»ýµÇ´Â ȯÀÚ¶ó¸é ICS Áö¼Ó »ç¿ë ¿©ºÎ °áÁ¤ ¹× roflumilast ¶Ç´Â azithromycin µîÀ¸·ÎÀÇ Àüȯ ¹× Ãß°¡ Ä¡·á¸¦ À§ÇÏ¿©, Àü¹®°¡¿¡°Ô ÀÇ·ÚÇÏ´Â °ÍÀ» °í·ÁÇØ¾ß ÇÑ´Ù.10
References
1. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J: Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356:775-789.
2. Lee SH, Lee JH, Yoon HI, Park HY, Kim TH, Yoo KH, Oh YM, Jung KS, Lee SD, Lee SW: Change in inhaled corticosteroid treatment and COPD exacerbations: an analysis of real-world data from the KOLD/KOCOSS cohorts. Respir Res 2019, 20:62.
3. Crim C, Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Willits LR, Yates JC, Vestbo J: Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J 2009, 34:641-647.
4. Crim C, Dransfield MT, Bourbeau J, Jones PW, Hanania NA, Mahler DA, Vestbo J, Wachtel A, Martinez FJ, Barnhart F, et al: Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with vilanterol alone in patients with COPD. Ann Am Thorac Soc 2015, 12:27-34.
5. Brassard P, Suissa S, Kezouh A, Ernst P: Inhaled corticosteroids and risk of tuberculosis in patients with respiratory diseases. Am J Respir Crit Care Med 2011, 183:675-678.
6. Wedzicha JA, Banerji D, Chapman KR, Vestbo J, Roche N, Ayers RT, Thach C, Fogel R, Patalano F, Vogelmeier CF: Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med 2016, 374:2222-2234.
7. Papi A, Vestbo J, Fabbri L, Corradi M, Prunier H, Cohuet G, Guasconi A, Montagna I, Vezzoli S, Petruzzelli S, et al: Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet 2018, 391:1076-1084.
8. Lipson DA, Barnhart F, Brealey N, Brooks J, Criner GJ, Day NC, Dransfield MT, Halpin DMG, Han MK, Jones CE, et al: Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N Engl J Med 2018, 378:1671-1680.
9. Watz H, Tetzlaff K, Wouters EF, Kirsten A, Magnussen H, Rodriguez-Roisin R, Vogelmeier C, Fabbri LM, Chanez P, Dahl R, et al: Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med 2016, 4:390-398.
10. Viniol C, Vogelmeier CF: Exacerbations of COPD. Eur Respir Rev 2018, 27.
THE MOST webmaster@mostonline.co.kr
<ÀúÀÛ±ÇÀÚ © THE MOST, ¹«´Ü ÀüÀç ¹× Àç¹èÆ÷ ±ÝÁö>